Pulmovant announced that the Phase 2 PHocus clinical trial of its inhaled dry powder mosliciguat in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD) has completed enrollment, and the company expects to report topline data later this year. A second Phase 2 trial called PHactor, which is evaluating inhaled mosliciguat plus inhaled treprostinil in PH-ILD patients, is underway.
In September 2024, parent company Roivant announced that Pulmovant was developing the mosliciguat DPI, which it had licensed from Bayer. According to the study record, the trial was initiated in October 2024 with an estimated enrollment of 120 PH-ILD patients.
Pulmovant CEO Drew Fromkin commented, “Completing enrollment of the PHocus study in less than one year from first patient dosed underscores the strong demand for new therapeutic options for patients suffering from PH-ILD. People living with PH-ILD have limited treatment options as current therapies are often poorly tolerated and require multiple doses per day, contributing to a high treatment burden. This milestone is a remarkable achievement and a testament to the dedication of the study participants and investigators as well as the Pulmovant team’s execution. We are deeply grateful for their collaboration in advancing mosliciguat’s development, which brings us closer to a potentially differentiated treatment for patients with PH-ILD and may also benefit patients with other conditions associated with pulmonary hypertension and pulmonary disorders more broadly.”
Read the Pulmovant press release
